Physician profile
Bobby Ghosh
NPI 1114156080
$7,096.47
in general payments reported to CMS, 2019-2025
29 companies · $2,529 in 2025
The $2,529 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,491 · 2020: $63.31 · 2021: $271 · 2022: $444 · 2023: $565 · 2024: $733 · 2025: $2,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402 · Travel and Lodging: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.15 |
| Travel and Lodging | $1,425.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,947.01 | 2023-2025 | Corevalve Evolut R, Symplicity G3 |
| Abbott Laboratories | $1,735.94 | 2019-2020 | |
| Abiomed | $451.99 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $251.17 | 2023-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $237.11 | 2023-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.27 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $209.51 | 2019-2022 | |
| Medtronic Vascular, INC. | $187.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $182.93 | 2023-2024 | Xarelto |
| Shockwave Medical, INC | $157.63 | 2022 | |
| Opsens INC. | $156.58 | 2019 | |
| Amgen INC. | $145.51 | 2023-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $144.01 | 2019-2025 | Farxiga, Lokelma |
| Pfizer INC. | $137.66 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $136.69 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.73 | 2022-2025 | Wegovy, Ozempic |
| Daiichi Sankyo INC. | $105.19 | 2024-2025 | Injectafer |
| Celonova Biosciences, INC. | $96.11 | 2019 | |
| Boston Scientific Corporation | $93.47 | 2020-2024 | Bodyguardian |
| Atricure, INC. | $85.45 | 2024 | |
| Cardiovascular Systems INC. | $77.27 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $46.57 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.32 | 2022-2023 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $34.01 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $30.55 | 2025 | |
| Amarin Pharma, INC. | $17.59 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.17 | 2023 | Arcalyst |
| Chiesi USA, INC. | $16.88 | 2024 | Kengreal |
| Smith+Nephew, INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Ghosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.